Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.52 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.47 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.47 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.46 |
| ▸ | CDK1 | P06493 | 2/20 | 0.45 |
| ▸ | CCNB1 | P14635 | 2/20 | 0.45 |
| ▸ | CCNA2 | P20248 | 2/20 | 0.45 |
| ▸ | CDK2 | P24941 | 2/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5652335 | 0.93 | TSHR (0.55) | TSHRCYP2C9CYP2D6MAPK14LMNA | |
| SCHEMBL5650178 | 0.92 | TSHR (0.54) | TSHRCYP2C9CYP2D6MAPK14LMNA | |
| SCHEMBL5651713 | 0.89 | CYP2D6 (0.59) | TSHRCYP2C9CYP2D6MAPK14CCNA2 | |
| SCHEMBL5651162 | 0.88 | TSHR (0.51) | TSHRCYP2C9CYP2D6MAPK14ALDH1A1 | |
| SCHEMBL5653003 | 0.88 | TSHR (0.56) | TSHRCYP2C9CYP2D6MAPK14LMNA | |
| SCHEMBL5651785 | 0.87 | TSHR (0.52) | TSHRCYP2C9CYP2D6MAPK14CDK1 | |
| SCHEMBL5648391 | 0.85 | ALDH1A1 (0.50) | TSHRCYP2C9CYP2D6MAPK14CDK1 | |
| SCHEMBL5651519 | 0.85 | FLT3 (0.45) | — | |
| SCHEMBL5650897 | 0.81 | CD274 (0.46) | TSHRCYP2C9CYP2D6LMNAPOLB | |
| SCHEMBL5652799 | 0.81 | GAA (0.41) | TSHRALDH1A1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7220769-B2 | Azolylbenzamides and analogues and their use for treating osteoporosis | NIKEM RESEARCH S.R.L. (IT) | 2007-05-22 | — | — | US | disclosed |
| US-20050038095-A1 | Azolylbenzamides and analogues and their use for treating osteoporosis | 3-V BIOSCIENCES, INC. | 2005-02-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050038095-A1 | Azolylbenzamides and analogues and their use for treating osteoporosis | NR0B2, NR0B1, NCOR1 | TSHR 161/4885CYP2C9 3314/4885CYP2D6 3252/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.